Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.

Willoughby CE, Jiang Y, Thomas HD, Willmore E, Kyle S, Wittner A, Phillips N, Zhao Y, Tudhope SJ, Prendergast L, Junge G, Madia Lourenco L, Finlay MRV, Turner P, Munck JM, Griffin RJ, Rennison T, Pickles J, Cano C, Newell DR, Reeves HL, Ryan AJ, Wedge SR.

J Clin Invest. 2019 Oct 3. pii: 127483. doi: 10.1172/JCI127483. [Epub ahead of print]

2.

Early Experience of Trans-arterial Chemo-Embolisation for Hepatocellular Carcinoma with a Novel Radiopaque Bead.

Reicher J, Mafeld S, Priona G, Reeves HL, Manas DM, Jackson R, Littler P.

Cardiovasc Intervent Radiol. 2019 Nov;42(11):1563-1570. doi: 10.1007/s00270-019-02317-3. Epub 2019 Aug 27.

3.

Acquired Hemophilia A After Nivolumab Therapy in a Patient With Metastatic Squamous Cell Carcinoma of the Lung Successfully Managed With Rituximab.

Gokozan HN, Friedman JD, Schmaier AH, Downes KA, Farah LA, Reeves HM.

Clin Lung Cancer. 2019 Sep;20(5):e560-e563. doi: 10.1016/j.cllc.2019.06.022. Epub 2019 Jun 26. No abstract available.

PMID:
31311716
4.

Absolute immature platelet count dynamics of thrombotic thrombocytopenic purpura patients with high ADAMTS13 inhibitor.

Gokozan HN, Reeves HM, Maitta RW.

Thromb Res. 2019 Jul;179:128-131. doi: 10.1016/j.thromres.2019.05.011. Epub 2019 May 18. No abstract available.

PMID:
31129448
5.

Characterization of the urinary metabolic profile of cholangiocarcinoma in a United Kingdom population.

Alsaleh M, Barbera TA, Reeves HL, Cramp ME, Ryder S, Gabra H, Nash K, Shen YL, Holmes E, Williams R, Taylor-Robinson SD.

Hepat Med. 2019 May 3;11:47-67. doi: 10.2147/HMER.S193996. eCollection 2019.

6.

From NASH to HCC: current concepts and future challenges.

Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M.

Nat Rev Gastroenterol Hepatol. 2019 Jul;16(7):411-428. doi: 10.1038/s41575-019-0145-7. Review.

PMID:
31028350
7.

Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.

Pelusi S, Baselli G, Pietrelli A, Dongiovanni P, Donati B, McCain MV, Meroni M, Fracanzani AL, Romagnoli R, Petta S, Grieco A, Miele L, Soardo G, Bugianesi E, Fargion S, Aghemo A, D'Ambrosio R, Xing C, Romeo S, De Francesco R, Reeves HL, Valenti LVC.

Sci Rep. 2019 Mar 6;9(1):3682. doi: 10.1038/s41598-019-39998-2.

8.

The CCR2+ Macrophage Subset Promotes Pathogenic Angiogenesis for Tumor Vascularization in Fibrotic Livers.

Bartneck M, Schrammen PL, Möckel D, Govaere O, Liepelt A, Krenkel O, Ergen C, McCain MV, Eulberg D, Luedde T, Trautwein C, Kiessling F, Reeves H, Lammers T, Tacke F.

Cell Mol Gastroenterol Hepatol. 2019;7(2):371-390. doi: 10.1016/j.jcmgh.2018.10.007. Epub 2018 Oct 18.

9.

Weighing the benefits of hepatocellular carcinoma surveillance against potential harms.

Geh D, Rana FA, Reeves HL.

J Hepatocell Carcinoma. 2019 Jan 14;6:23-30. doi: 10.2147/JHC.S159581. eCollection 2019. Review.

10.

Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View.

Tiniakos DG, Maurício J, Reeves HL.

Adv Exp Med Biol. 2018;1032:55-69. doi: 10.1007/978-3-319-98788-0_4. Review.

PMID:
30362090
11.

Reply to 'Comment on 'Circulating Neutrophils in patients with hepatocellular carcinoma".

Chan SL, McNally RJQ, Reeves HL.

Br J Cancer. 2018 Sep;119(6):781-782. doi: 10.1038/s41416-018-0250-3. Epub 2018 Sep 12. No abstract available.

12.

Liquid biopsy for liver diseases.

Mann J, Reeves HL, Feldstein AE.

Gut. 2018 Dec;67(12):2204-2212. doi: 10.1136/gutjnl-2017-315846. Epub 2018 Sep 3. Review.

PMID:
30177542
13.

Community change and resident needs: Designing a Participatory Action Research study in Metropolitan Boston.

Arcaya MC, Schnake-Mahl A, Binet A, Simpson S, Church MS, Gavin V, Coleman B, Levine S, Nielsen A, Carroll L, Ursprung S, Wood B, Reeves H, Keppard B, Sportiche N, Partirdge J, Figueora J, Frakt A, Alfonzo M, Abreu D, Abreu T, Ambroise T, Andrade E, Barrientos E, Baty A, Baty C, Benner K, Bennett C, Blanchette A, Bongiovanni R, Cardile O, Corchado C, Dixon C, Dodson C, Dominguez J, Durena M, Fiestas Y, Genty J, Graffam N, Gonzalez A, Grigsby E, Hayden P, Alvado SH, Hernandez Z, Hodes I, Johnson J, Keefe K, Latimer K, Levine S, Logg C, Martinez N, Mboup K, McPhorson D, Meacham S, Mohammed D, Moss E, Nielsen A, O'Brien K, Owens L, Partridge J, Johnson LP, Power MB, Rebelo T, Remy R, Roderigues G, Sabtow Q, Sanchez C, Seeder A, Sepulveda R, Sportiche N, Ursprung S, West E, Winters L, Wood B, Youmans T.

Health Place. 2018 Jul;52:221-230. doi: 10.1016/j.healthplace.2018.05.014. Epub 2018 Jul 6.

14.

Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR).

Burt AD, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, Kakar S, Ng I, Park YN, Reeves H, Wyatt J, Yeh MM, Ellis DW.

Histopathology. 2018 Sep;73(3):369-385. doi: 10.1111/his.13520. Epub 2018 May 30. Review.

PMID:
29573451
15.

The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury.

Barbier-Torres L, Iruzubieta P, Fernández-Ramos D, Delgado TC, Taibo D, Guitiérrez-de-Juan V, Varela-Rey M, Azkargorta M, Navasa N, Fernández-Tussy P, Zubiete-Franco I, Simon J, Lopitz-Otsoa F, Lachiondo-Ortega S, Crespo J, Masson S, McCain MV, Villa E, Reeves H, Elortza F, Lucena MI, Hernández-Alvarez MI, Zorzano A, Andrade RJ, Lu SC, Mato JM, Anguita J, Rincón M, Martínez-Chantar ML.

Nat Commun. 2017 Dec 12;8(1):2068. doi: 10.1038/s41467-017-01970-x.

16.

NAFLD-which patients should have hepatocellular carcinoma surveillance?

Elcioglu ZC, Reeves HL.

Hepatobiliary Surg Nutr. 2017 Oct;6(5):353-355. doi: 10.21037/hbsn.2017.06.04. No abstract available.

17.

Neutrophils: driving progression and poor prognosis in hepatocellular carcinoma?

Margetts J, Ogle LF, Chan SL, Chan AWH, Chan KCA, Jamieson D, Willoughby CE, Mann DA, Wilson CL, Manas DM, Yeo W, Reeves HL.

Br J Cancer. 2018 Jan;118(2):248-257. doi: 10.1038/bjc.2017.386. Epub 2017 Nov 9.

18.

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Donati B, Pietrelli A, Pingitore P, Dongiovanni P, Caddeo A, Walker L, Baselli G, Pelusi S, Rosso C, Vanni E, Daly A, Mancina RM, Grieco A, Miele L, Grimaudo S, Craxi A, Petta S, De Luca L, Maier S, Soardo G, Bugianesi E, Colli F, Romagnoli R, Anstee QM, Reeves HL, Fracanzani AL, Fargion S, Romeo S, Valenti L.

Cancer Med. 2017 Aug;6(8):1930-1940. doi: 10.1002/cam4.1078. Epub 2017 Jul 4.

19.

MBOAT7 rs641738 variant and hepatocellular carcinoma in non-cirrhotic individuals.

Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, Miele L, Petta S, Maier S, Rosso C, De Luca L, Vanni E, Grimaudo S, Romagnoli R, Colli F, Ferri F, Mancina RM, Iruzubieta P, Craxi A, Fracanzani AL, Grieco A, Corradini SG, Aghemo A, Colombo M, Soardo G, Bugianesi E, Reeves H, Anstee QM, Fargion S, Valenti L.

Sci Rep. 2017 Jul 3;7(1):4492. doi: 10.1038/s41598-017-04991-0.

20.

Opposite effects of a glucokinase activator and metformin on glucose-regulated gene expression in hepatocytes.

Al-Oanzi ZH, Fountana S, Moonira T, Tudhope SJ, Petrie JL, Alshawi A, Patman G, Arden C, Reeves HL, Agius L.

Diabetes Obes Metab. 2017 Aug;19(8):1078-1087. doi: 10.1111/dom.12910. Epub 2017 Apr 10.

PMID:
28206714
21.

Dynamic changes in absolute immature platelet count suggest the presence of a coexisting immune process in the setting of thrombotic thrombocytopenic purpura.

Stefaniuk CM, Reeves HM, Maitta RW.

Transfusion. 2017 Apr;57(4):913-918. doi: 10.1111/trf.13974. Epub 2017 Jan 12.

PMID:
28083876
22.

Unexpected Non-Maternally Derived Anti-PP1Pk in an 11-Week-Old Patient.

Reeves HM, Cary V, Mino MA, McGrath C, Westra JA, Piccone C, Downes KA.

J Pediatr. 2017 Feb;181:302-305. doi: 10.1016/j.jpeds.2016.10.042. Epub 2016 Nov 14.

PMID:
27852457
23.

Urinary Metabotyping of Hepatocellular Carcinoma in a UK Cohort Using Proton Nuclear Magnetic Resonance Spectroscopy.

Shariff MI, Kim JU, Ladep NG, Crossey MM, Koomson LK, Zabron A, Reeves H, Cramp M, Ryder S, Greer S, Cox IJ, Williams R, Holmes E, Nash K, Taylor-Robinson SD.

J Clin Exp Hepatol. 2016 Sep;6(3):186-194. Epub 2016 Apr 20.

24.

Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease.

Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S.

QJM. 2017 Feb 1;110(2):73-81. doi: 10.1093/qjmed/hcw151.

25.

Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma.

Alhasan SF, Haugk B, Ogle LF, Beale GS, Long A, Burt AD, Tiniakos D, Televantou D, Coxon F, Newell DR, Charnley R, Reeves HL.

Br J Cancer. 2016 Sep 27;115(7):797-804. doi: 10.1038/bjc.2016.264. Epub 2016 Aug 25.

26.

Comparison of two apheresis systems during hematopoietic progenitor stem cell collections at a tertiary medical center.

Li Y, Li J, Reeves HM, Reyes R, Maitta RW.

Transfusion. 2016 Nov;56(11):2833-2838. doi: 10.1111/trf.13754. Epub 2016 Aug 3.

PMID:
27487161
27.

Combination PARP and HDAC inhibition as a therapeutic strategy targeting liver cancer stem cells?

Willoughby CE, Reeves HL.

Chin Clin Oncol. 2016 Oct;5(5):60. doi: 10.21037/cco.2016.03.21. Epub 2016 Apr 12. No abstract available.

28.

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NJ, Jamieson D, Reeves HL.

J Hepatol. 2016 Aug;65(2):305-13. doi: 10.1016/j.jhep.2016.04.014. Epub 2016 Apr 27.

PMID:
27132171
29.

Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases.

Reuillon T, Alhasan SF, Beale GS, Bertoli A, Brennan A, Cano C, Reeves HL, Newell DR, Golding BT, Miller DC, Griffin RJ.

Chem Sci. 2016 Apr 21;7(4):2821-2826. doi: 10.1039/c5sc03612g. Epub 2016 Jan 11.

30.

A national survey of the provision of ultrasound surveillance for the detection of hepatocellular carcinoma.

Cross TJS, Villanueva A, Shetty S, Wilkes E, Collins P, Adair A, Jones RL, Foxton MR, Meyer T, Stern N, Warshow U, Khan N, Prince M, Khakoo S, Alexander GJ, Khan S, Reeves H, Marshall A, Williams R.

Frontline Gastroenterol. 2016 Apr;7(2):82-89. doi: 10.1136/flgastro-2015-100617. Epub 2015 Dec 7. Erratum in: Frontline Gastroenterol. 2019 Jan;10(1):87.

31.

Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade.

Toyoda H, Lai PB, O'Beirne J, Chong CC, Berhane S, Reeves H, Manas D, Fox RP, Yeo W, Mo F, Chan AW, Tada T, Iñarrairaegui M, Vogel A, Schweitzer N, Chan SL, Sangro B, Kumada T, Johnson PJ.

Br J Cancer. 2016 Mar 29;114(7):744-50. doi: 10.1038/bjc.2016.33.

32.

Imaging changes after breast reconstruction with fat grafting - Retrospective study of 90 breast cancer.

Noor L, Reeves HR, Kumar D, Alozairi O, Bhaskar P.

Pak J Med Sci. 2016 Jan-Feb;32(1):8-12. doi: 10.12669/pjms.321.9460.

33.

Hepatocellular Carcinoma in Obesity, Type 2 Diabetes, and NAFLD.

Reeves HL, Zaki MY, Day CP.

Dig Dis Sci. 2016 May;61(5):1234-45. doi: 10.1007/s10620-016-4085-6. Epub 2016 Feb 26. Review.

PMID:
26921078
34.

Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients.

Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechêne A, Gerken G, Schlaak JF, Weinmann A, Wörns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P.

Clin Gastroenterol Hepatol. 2016 Jun;14(6):875-886.e6. doi: 10.1016/j.cgh.2015.12.042. Epub 2016 Jan 13.

PMID:
26775025
35.

A Semi-Structured MODFLOW-USG Model to Evaluate Local Water Sources to Wells for Decision Support.

Feinstein DT, Fienen MN, Reeves HW, Langevin CD.

Ground Water. 2016 Jul;54(4):532-44. doi: 10.1111/gwat.12389. Epub 2016 Jan 12.

PMID:
26757094
36.

Assessment of the Hong Kong Liver Cancer Staging System in Europe.

Kolly P, Reeves H, Sangro B, Knöpfli M, Candinas D, Dufour JF.

Liver Int. 2016 Jun;36(6):911-7. doi: 10.1111/liv.13045. Epub 2016 Jan 21.

PMID:
26677809
37.

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.

Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FE, Jamieson D.

Int J Cancer. 2016 Jan 1;138(1):206-16. doi: 10.1002/ijc.29680. Epub 2015 Aug 19.

38.

Hepatocellular carcinoma: optimal staging impacts survival.

Reeves HL, Aisen AM.

Gastroenterology. 2015 Jun;148(7):1274-6. doi: 10.1053/j.gastro.2015.04.026. Epub 2015 Apr 25. No abstract available.

PMID:
25921373
39.

Regioselective sulfamoylation at low temperature enables concise syntheses of putative small molecule inhibitors of sulfatases.

Miller DC, Carbain B, Beale GS, Alhasan SF, Reeves HL, Baisch U, Newell DR, Golding BT, Griffin RJ.

Org Biomol Chem. 2015 May 14;13(18):5279-84. doi: 10.1039/c5ob00211g.

PMID:
25858034
40.

Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.

Piguet AC, Saran U, Simillion C, Keller I, Terracciano L, Reeves HL, Dufour JF.

J Hepatol. 2015 Jun;62(6):1296-303. doi: 10.1016/j.jhep.2015.01.017. Epub 2015 Jan 23.

41.

Reply to: HCC and liver disease risk in homozygous PNPLA3 p.I148M carriers approach monogenic inheritance.

Anstee QM, Liu YL, Day CP, Reeves HL.

J Hepatol. 2015 Apr;62(4):982-3. doi: 10.1016/j.jhep.2014.12.028. Epub 2015 Jan 2. No abstract available.

42.

Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade.

Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H.

J Clin Oncol. 2015 Feb 20;33(6):550-8. doi: 10.1200/JCO.2014.57.9151. Epub 2014 Dec 15.

43.

DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival.

Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, Televantou D, Thomas HD, Jackson J, Burt AD, Newell D, Rose J, Manas DM, Shapiro GI, Curtin NJ, Reeves HL.

Clin Cancer Res. 2015 Feb 15;21(4):925-33. doi: 10.1158/1078-0432.CCR-14-0842. Epub 2014 Dec 5.

44.

A longitudinal field trial assesing the impact of feeding waste milk containing antibiotic residues on the prevalence of ESBL-producing Escherichia coli in calves.

Brunton LA, Reeves HE, Snow LC, Jones JR.

Prev Vet Med. 2014 Nov 15;117(2):403-12. doi: 10.1016/j.prevetmed.2014.08.005. Epub 2014 Aug 14.

PMID:
25172121
45.

Absolute immature platelet count helps differentiate thrombotic thrombocytopenic purpura from hypertension-induced thrombotic microangiopathy.

Zheng Y, Hong H, Reeves HM, Maitta RW.

Transfus Apher Sci. 2014 Aug;51(1):54-7. doi: 10.1016/j.transci.2014.07.004. Epub 2014 Jul 28.

PMID:
25130726
46.

TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease.

Liu YL, Reeves HL, Burt AD, Tiniakos D, McPherson S, Leathart JB, Allison ME, Alexander GJ, Piguet AC, Anty R, Donaldson P, Aithal GP, Francque S, Van Gaal L, Clement K, Ratziu V, Dufour JF, Day CP, Daly AK, Anstee QM.

Nat Commun. 2014 Jun 30;5:4309. doi: 10.1038/ncomms5309.

47.

A positive feedback loop between RIP3 and JNK controls non-alcoholic steatohepatitis.

Gautheron J, Vucur M, Reisinger F, Cardenas DV, Roderburg C, Koppe C, Kreggenwinkel K, Schneider AT, Bartneck M, Neumann UP, Canbay A, Reeves HL, Luedde M, Tacke F, Trautwein C, Heikenwalder M, Luedde T.

EMBO Mol Med. 2014 Aug;6(8):1062-74. doi: 10.15252/emmm.201403856.

48.

Characterization of the invasiveness of monophasic and aphasic Salmonella Typhimurium strains in 1-day-old and point-of-lay chickens.

Martelli F, Gosling R, Kennedy E, Rabie A, Reeves H, Clifton-Hadley F, Davies R, La Ragione R.

Avian Pathol. 2014;43(3):269-75. doi: 10.1080/03079457.2014.917759.

PMID:
24802091
49.

Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.

Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, Day CP, Daly AK, Reeves HL, Anstee QM.

J Hepatol. 2014 Jul;61(1):75-81. doi: 10.1016/j.jhep.2014.02.030. Epub 2014 Mar 6.

PMID:
24607626
50.

Reply to "Hepatocellular carcinoma and the Newcastle-upon-Tyne area".

Anstee QM, Jaques B, Hudson M, Reeves HL.

J Hepatol. 2014 Jun;60(6):1330-1. doi: 10.1016/j.jhep.2014.02.017. Epub 2014 Mar 3. No abstract available.

Supplemental Content

Loading ...
Support Center